FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma
The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
Related Articles
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Oncology Overdrive | 2024 Episodes | Healio Podcasts
A podcast hosted by Shikha Jain, MD, FACP, covering modern day health care in an ever-evolving world. Watch 2024 episodes on Healio today.
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Voice-Based Screening May Predict Risk of Major Depression : Oncology Times
An abstract is unavailable.
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported…
Evolving Paradigms In Advanced Ovarian Cancer Care
Navigate the evolving paradigms in advanced ovarian cancer care. Delve into the latest treatments and methodologies improving patient outcomes.
FDA Approves HER2 Test as Companion Diagnostic for Zanidatamab in Biliary Tract Cancer
The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.
ASH Annual Meeting Abstracts
Late-breaking abstracts feature substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at…
